Managing Postprandial Hyperglycemia with Available Medications

Introduction to Medications

The American Diabetes Association recommends acarbose, an alpha-glucosidase inhibitor, as a treatment option for managing postprandial hyperglycemia, which reduces postprandial blood glucose by inhibiting carbohydrate absorption in the upper small intestine 1
The European Association for the Study of Diabetes suggests that repaglinide, a meglitinide, can be used to reduce postprandial blood glucose by stimulating insulin secretion in the early phase 1

Acarbose is particularly suitable for patients who consume carbohydrates as their main food ingredient and experience postprandial hyperglycemia, with a low risk of hypoglycemia when used alone 1
Common adverse reactions to acarbose include gastrointestinal effects such as abdominal distension and flatulence, which can be minimized by starting with a small dose and gradually increasing 1

The American College of Clinical Endocrinologists recommends glipizide and gliclazide, second-generation sulfonylureas, which lower glycemia by enhancing insulin secretion and can reduce HbA1c levels by approximately 1.5 percentage points 2
Second-generation sulfonylureas are associated with a lower risk of hypoglycemia compared to first-generation agents, although hypoglycemia can still be a major adverse side effect 2

The International Diabetes Federation suggests that sitagliptin and saxagliptin, DPP-4 inhibitors, increase endogenous levels of GLP-1 by reducing its deactivation, enhancing insulin secretion and inhibiting glucagon secretion in a glucose-dependent manner, with a minimal risk of hypoglycemia when used as monotherapy 1
DPP-4 inhibitors reduce HbA1c levels by approximately 0.4% to 0.9% and have a neutral effect on weight 1

The American Diabetes Association recommends metformin, a biguanide, which primarily targets fasting glucose by reducing hepatic glucose production, but also helps manage postprandial hyperglycemia by improving insulin sensitivity, and is generally considered weight-neutral with chronic use 5
Metformin does not increase the risk of hypoglycemia, but is associated with initial gastrointestinal side effects, and caution is advised to avoid its use in patients at risk for lactic acidosis 5

The European Association for the Study of Diabetes suggests that combination therapy, such as DPP-4 inhibitors with metformin, may be necessary for optimal management of postprandial hyperglycemia, providing comprehensive glycemic control 6
Alpha-glucosidase inhibitors can be used in combination with biguanides, sulfonylureas, or insulin, although careful consideration of the patient's clinical characteristics is necessary 1